# RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure

Source: https://onco.cc/trials/nct07366840/  
OnCo record `nct07366840` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Disitamab vedotin, Gemcitabine, Capecitabine, Trastuzumab and Inetetamab in HER2-positive breast cancer and Breast cancer, run by Fudan University, not yet recruiting.

## Summary

RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure is a phase 2/3 interventional study registered as NCT07366840 by Fudan University, with 268 participants planned, started 2026-01-16 and due to reach its primary completion in 2028-01-16. Interventions recorded: Disitamab Vedotin, Gemcitabine, Capecitabine, Trastuzumab, Inetetamab. Conditions recorded: HER2-positive Breast Cancer, Metastatic Breast Cancer.

Linked to the drug Inetetamab because the registry names it among its interventions and HER2-positive breast cancer and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07366840
- Phase: 2/3
- Setting: A Phase 3, Randomized Advanced Breast Cancer Study Investigating RC48 Combined With Chemotherapy Versus Guideline-recommended Trastuzumab/Inetetamab Plus Chemotherapy in HER2-Positive Patients With Prior TOP1i-ADC Failure
- Sponsor: Fudan University
- Enrolled: 268

## Sources

- ClinicalTrials.gov NCT07366840: https://clinicaltrials.gov/study/NCT07366840

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Inetetamab](https://onco.cc/drugs/inetetamab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)

---
JSON: https://onco.cc/api/v1/entities/nct07366840.json